Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Investor Day (June 2026)
97 slides from Elekta Ab Class B's investor day presentation, Jun 17, 2026
Slide 1: Capital Markets Day: Leading the shift to adaptive radiotherapy
Capital Markets Day Leading the shift to adaptive radiotherapy June 17, 2026 Stockholm
Slide 2: The Elekta team today
The Elekta team today Jakob Klara Christopher Arnaud Ardie Anming Peter Just-Bomholt Eiritz Busch Delhaye Ermers Gong Nyquist President Chief Financial Chief Product and Head of Region Head of Region Head of Region Head of Investor & CEO Officer Technology Officer Europe Americas China Relations 2
Slide 3: Agenda
Agenda Speaker Time 1 Welcome & Introduction Peter Nyquist, Head of Investor Relations 5 min 2 Strategy & Targets Jakob Just-Bomholt, President & CEO 20 min Christopher Busch 3 Linac & Software Products Chief Product and Technology Officer 25 min Break 15 min Arnaud Delhaye, Head of Region Europe 4
Slide 4: Important information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward-looking statements are based on current expectations about future event
Slide 5: Agenda
Agenda Speaker Time 1 Welcome & Introduction Peter Nyquist, Head of Investor Relations 5 min 2 Strategy & Targets Jakob Just-Bomholt, President & CEO 20 min Christopher Busch 3 Linac & Software Products Chief Product and Technology Officer 25 min Break 15 min Arnaud Delhaye, Head of Region Europe 4
Slide 6: Setting the standard of care to bring hope to more patients
For 50 years Elekta has shaped the standard of care Setting the 27+ countries with online 6000+ centers with Elekta technology standard of care adaptive treatments to bring hope to 2M+ patients 7,500+ Elekta more patients treated each year systems globally We are the largest independent radiation on
Slide 7: Radiotherapy is uniquely positioned to address the cancer care gap
Strategy & Targets Radiotherapy is uniquely positioned to address the cancer care gap Cancer burden has grown faster than skilled Radiotherapy remains a scalable, cost-efficient professionals solution to address the cancer care gap 30 • Precision radiotherapy is needed in >50% of all cancer treatmen
Slide 8: Radiotherapy market delivers resilient and consistent growth with predictable recurring sales
Strategy & Targets Radiotherapy market delivers resilient and consistent growth with predictable recurring sales Business model provides steady earnings for 10+ RT market has grown at 6% CAGR L5Y, BUSD years across lifecycle Device & software bundled sales 6% 7,1 Upgrades 6,7 6,2 lution sale 5,5 5,7
Slide 9: Clinical adoption of Adaptive Radiotherapy is the next frontier
Strategy & Targets Clinical adoption of Adaptive Radiotherapy (ART) is the next frontier for our industry Better imaging enhances precision and strengthens confidence in dose delivery Faster processing accelerates adaptive replanning Higher confidence in dose delivery combined with faster adaptive r
Slide 10: Elekta is uniquely positioned to lead adaptive precision radiotherapy
Strategy & Targets Elekta is uniquely positioned to lead adaptive precision radiotherapy Vision A world where everyone has access to the best cancer care • Leader in precision radiotherapy Our ambition • Expand patient access to advanced radiotherapy treatments worldwide • Leading positions in radio
Slide 11: Strong portfolio logic focused on precision, image guided and adaptive radiotherapy
Strategy & Targets Elekta has a strong portfolio logic and are 100% focused on precision, image guided and adaptive radiotherapy CT-Linacs MR-Linac Elekta ONE Brachy Neuro Software Suite 11
Slide 12: Clear #1 position in Neuro, Brachy and MR-Linac; #2 in CT-Linac and Software
Strategy & Targets Elekta has clear #1 market leader position in Neuro, Brachy and MR-Linac; #2 positions in CT-Linac and Software MR-Linac Total Radiotherapy market 2025, by geography 1 ~18k 7.1BUSD Brachy CT-Linac #1 Europe ~25% 25–30% #1 #2 United States ~25% 30–35% China ~15% ~10% Other markets
Slide 13: Turnaround will be executed in three phases
Strategy & Targets Elekta today is not operating at our full potential; turnaround will be executed in three phases 3 Innovation driven growth • Continued strong investment in 2 Improve profitability R&D ~10% of revenue • Steady stream of new products 1 Reset and Stabilize • Focused and commercially
Slide 14: Four Must-Win Battles
Strategy & Targets Four Must-Win Battles will accelerate Elekta towards continued profitable growth Simplify, Empower, Speed Focused Innovation Profitable Expand in China growth Continuous COGS Win in the U.S. Reduction 14
Slide 15: Outlook for FY26/27
Strategy & Targets Outlook for FY26/27 Sales Growth in fixed currency Adjusted EBIT Margin1 2 – 4% 12.5 – 13.5% 1 Adjusted fo r Items Affecting Comparab ility (IA C), and assu me s amortizatio n b roadly in lin e with cap italization 15
Slide 16: Mid-term financial targets until FY28/29
Strategy & Targets Mid-term financial targets until FY28/29 Sales Growth Free cash flow CAGR FY25/26 – FY28/29 Adjusted EBIT Margin1 before dividends in fixed currency FY28/29 FY28/29 Mid-single 14 – 16% ~10% digit as % of sales as % of sales 1 Adjusted fo r Items Affecting Comparab ility (IA C), an
Slide 17: Mid-single digit sales growth expected to accelerate during three-year period
Strategy & Targets Mid-single digit sales growth is expected to accelerate during three- year period, ambition to grow at or above market in future years Elekta sales development, BSEK Growth in constant currency Key growth drivers: 2-4% • Product releases 1% 1% • Software and service expansion • U.
Slide 18: Service and Software will support mid-single digit sales growth
Strategy & Targets Service and Software will support mid-single digit sales growth and improved gross margins Solution So Software platform f Continued SaaS and cloud-based adoption tw Adaptive integration with our solutions s are de Solution Sales AI-enabled workflow and productivity Upgra (SaaS) E
Slide 19: Summary
Strategy & Targets Summary Radiotherapy is an attractive segment Elekta has a strong, market leading and focused product portfolio Elekta today is not operating at full potential Turnaround will be executed in three phases Sales growth is expected to accelerate in the next three years with mid-singl
Slide 20: Agenda
Agenda Speaker Time 1 Welcome & Introduction Peter Nyquist, Head of Investor Relations 5 min 2 Strategy & Targets Jakob Just-Bomholt, President & CEO 20 min Christopher Busch 3 Linac & Software Products Chief Product and Technology Officer 25 min Break 15 min Arnaud Delhaye, Head of Region Europe 4
Slide 21: Portfolio past and present
Linac & Software Products Focused innovation Portfolio Industry Innovation past and trends agenda present 21
Slide 22: Portfolio past and present
Linac & Software Products Focused innovation Portfolio Industry Innovation past and trends agenda present 22
Slide 23: Building on Elekta's rich history of breakthrough innovations
Linac & Software Products Portfolio past and present We are building on Elekta’s rich history of breakthrough innovations Proud history of industry Continued investment in changing innovation innovation excellence 1960s 2000s 2000s 2010s 2020s Leksell Gamma Knife Image-Guided Volumetric Modulated MR
Slide 24: Elekta has a strong technology portfolio logic
Linac & Software Products Portfolio past and present Elekta has a strong technology portfolio logic Building solutions across our portfolio instead of isolated product initiatives CT-Linacs MR-Linac Elekta ONE Brachy Neuro Software Suite Integrating Elekta ONE workflows and Software, with top priori
Slide 25: Portfolio past and present
Linac & Software Products Focused innovation Portfolio Industry Innovation past and trends agenda present 25
Slide 26: Portfolio well positioned to address four industry trends
Linac & Software Products Industry trends Elekta’s portfolio is well positioned to address four industry trends Personalization and productivity are not contradictory 1 Safety, efficiency, and accessibility for online adaptive at scale require deep integration 2 Dose escalation continues towards (ul
Slide 27: Personalization and productivity are not contradictory
Linac & Software Products Industry trends 1 Personalization and productivity are not contradictory Elekta MR-Linac Elekta CT-Linac e P Highly ductivity r s onalization autonomous and efficient course of (adaptive) P ro treatment Enhanced clinical value Enhanced simplicity Building on recent, exponen
Slide 28: Safety, efficiency and accessibility for online adaptive require deep integration
Linac & Software Products Industry trends 2 Safety, efficiency, and accessibility for online adaptive at scale require deep integration tion Workflows increasingly evolve in minutes, not days, a m increasing potential for errors or Li n Sy nf m ac yi e st log Trend towards deeper integration of devi
Slide 29: Dose escalation continues towards (ultra-)hypofractionation
Linac & Software Products Industry trends 3 Dose escalation continues towards (ultra-)hypofractionation: Elekta’s MR-Linac enables a breakthrough in SBRT1 Hermes study – Clinical evidence ESTRO – Thought leaders z z Treating selected cohorts of prostate cancer patients in 2 fractions and ~1 hour in
Slide 30: Clinicians and reimbursement tiers favor uptake of complex treatments
Linac & Software Products Industry trends 4 Clinicians and reimbursement tiers favor uptake of complex treatments Reimbursement (U.S. example) Clinicians 70% Request ‘better motion management’ Shift of higher billing codes to sophisticated treatments based ESTRO surveyed professionals about Stereota
Slide 31: Innovation agenda
Linac & Software Products Focused innovation Portfolio Industry Innovation past and trends agenda present 31
Slide 32: Gross R&D expected to stabilize around 10% of sales
Linac & Software Products Innovation agenda Gross R&D is expected to stabilize around 10% of sales with accelerated innovation velocity Development of Gross R&D expenditures1 Focus over the last years 3.0 12.2% 12.2% • Increased share of investments in core 11.6% new product introductions 2.5 2.2 2.
Slide 33: Focused innovation agenda prioritizes accessible productivity in the clinic
Linac & Software Products Innovation agenda Elekta’s focused innovation agenda prioritizes accessible productivity in the clinic, combined with high-quality treatments 1 CT-Linacs 2 MR-Linac 3 Treatment 4 Oncology Planning Information System Portfolio: Drive adaptive Doubles potential 10x planning s
Slide 34: CT-Linac innovation agenda with product releases during next 12 months
Linac & Software Products Innovation agenda 1 CT-Linac innovation agenda with significant product feature releases during next 12 months CT-Linac Today Product feature releases over next 12 months A B Evo with online Iris AI supported high- = + Real-time organ motion adaptive definition imaging: ‘He
Slide 35: Iris: Next generation of high-definition imaging
Linac & Software Products Innovation agenda 1 A Iris®: Next generation of high-definition imaging More body sites, faster imaging rates, treatment plan-quality Cone-Beam CT images Iris Scaling + New Pelvis Head & Neck Brain 35
Slide 36: Real-time CT-linac organ motion management
Linac & Software Products Innovation agenda 1 B Real-time CT-linac organ motion management increasing treatment precision and options for hypofractionation • Real-time 3D tracking of internal motion using existing x-ray imaging • Software-driven innovation available to existing installed base • Pros
Slide 37: Integrated Console
Linac & Software Products Innovation agenda 1 C Integrated Console: CE approved for Harmony linac, broad Evo release expected 2027, together with Integrated 6D table Front end: Enhanced productivity, ease of use Workflow guidance Integrated imaging tools Large viewing area Continuous system monitori
Slide 38: Integrated 6D table
Linac & Software Products Innovation agenda 1 D Integrated 6D table: A step-up in treatment room workflow and accuracy Quick and accurate Increased patient positioning for automation through wide variety of treatments tighter software- including Stereotactic device integration Radiosurgery (SRS) and
Slide 39: Unity Pro is a step-change in MR-linac clinical productivity
Linac & Software Products Innovation agenda 2 Unity Pro is a step-change in MR-linac clinical productivity and customer ROI, doubling the achievable patient throughput MR Linac Today Releases over next 12 months = + New AI-enhanced MR Imaging packages AI-based MR auto- segmentation Doubles potential
Slide 40: Growing evidence of superior clinical value of Unity Pro
Linac & Software Products Innovation agenda 2 Growing evidence of superior clinical value of Unity Pro; High profile clinical trials show efficacy of treatment
Slide 41: Elekta ONE Planning boosts clinic throughput
Linac & Software Products Innovation agenda 3 Elekta ONE Planning boosts clinic throughput by speed and enables adaptive workflows e.g. through remote physician engagement Treatment Planning Today Releases over next 6 months Gynae 32 minutes 93% reduction 1.8 minutes = + Traditional planning GPU-acc
Slide 42: Elekta Oncology Information System enhanced performance and integration
Linac & Software Products Innovation agenda 4 Elekta Oncology Information System – Enhanced performance & integration to strengthen backbone of radiotherapy departments Workflow • Tighter integration across Elekta ONE ecosystem • Improved planning-to-treatment efficiency • Better interoperability wi
Slide 43: Summary
Linac & Software Products Summary ~10% Group gross R&D expenditures is the appropriate level to deliver a market leading portfolio R&D investments allocated to a focused innovation agenda prioritizing customer productivity Predictable, fast release cadence with highly impactful releases in next 6-12
Slide 44: Agenda
Agenda Speaker Time 1 Welcome & Introduction Peter Nyquist, Head of Investor Relations 5 min 2 Strategy & Targets Jakob Just-Bomholt, President & CEO 20 min Christopher Busch 3 Linac & Software Products Chief Product and Technology Officer 25 min Break 15 min Arnaud Delhaye, Head of Region Europe 4
Slide 45: Agenda
Agenda Speaker Time 1 Welcome & Introduction Peter Nyquist, Head of Investor Relations 5 min 2 Strategy & Targets Jakob Just-Bomholt, President & CEO 20 min Christopher Busch 3 Linac & Software Products Chief Product and Technology Officer 25 min Break 15 min Arnaud Delhaye, Head of Region Europe 4
Slide 46: Focus is on three key markets
Markets Focus is on three key markets United Europe China States Arnaud Delhaye Ardie Ermers Anming Gong Head of Region Head of Region Head of Region Europe Americas China 46
Slide 47: Focus is on three key markets
Markets Focus is on three key markets United Europe China States Arnaud Delhaye Ardie Ermers Anming Gong Head of Region Head of Region Head of Region Europe Americas China 47
Slide 48: Europe represents 25-30% of total RT market, growing at 4-6%
Europe Europe represents 25 – 30% of total RT market, growing at 4 – 6% fueled by adoption of adaptive radiotherapy Total Radiotherapy market 2025, by geography ~18k 7.1BUSD • Structural growth of RT as cost-effective and well reimbursed modality from public Europe ~25% ~25–30% investments • Technol
Slide 49: Strong growth in Europe, focus on market share and profitable growth
Europe Elekta has seen strong growth in Europe, focus is to expand market share and profitable growth Europe sales as share of Elekta Group sales, last 5 years Three commercial priorities for Europe, next 3 years BSEK Elekta ex. EU Europe 14.5 16.9 18.1 18.0 16.7 Upgrade our installed base and take
Slide 50: Major replacement cycle with ~1,000 linacs over next 3 years
Europe Evo is well suited for replacement cycle Major upcoming replacement cycle with ~1,000 linacs over next 3 years, adaptive is expected to be a key decision factor • Replacement wave with ~1,000 linacs to be replaced, over the next 3 years1 • Adaptive is the new standard with 70% of Elekta linac
Slide 51: Accelerating recurring software and service sales
Europe Focus on software and service growth Elekta will continue to focus on accelerating recurring software and service sales during the next phase Share or service and software sales, % +5 p.p. • Expansion of Elekta One Planning Software footprint and recurring sales • Continued shift to SaaS mode
Slide 52: Commercial execution through pricing, operations and account management
Europe Commercial execution Europe will focus on commercial execution through improved pricing, operations and account management Stronger Continuous Lifecycle Value-Based Service Value & Operations Account Pricing Attach Rates Improvements Management Higher ASP1 and Recurring sales Higher profitabi
Slide 53: Europe sales target CAGR FY25/26 – FY28/29
Europe Sales target CAGR FY25/26 – FY28/29 Europe FY25/26 Mid-term targets • Sales growth in fixed Mid-single digit currency 8% CAGR FY25/26 – FY28/29 53
Slide 54: Focus is on three key markets
Markets Focus is on three key markets United Europe China States Arnaud Delhaye Ardie Ermers Anming Gong Head of Region Head of Region Head of Region Europe Americas China 54
Slide 55: U.S. represents 30-35% of total RT market
United States U.S. represents 30 – 35% of total RT market, based on technology- driven replacements Total Radiotherapy market 2025, by geography • Replacement market with structural demand ~18k 7.1BUSD Europe ~25% 25–30% • Consistent decline in fractions delivered last two decades United States ~25%
Slide 56: Adaptive RT holds major reimbursement upside
United States Adaptive RT holds major reimbursement upside as conventional RT is pressured further RO clinics forced to drive toward SBRT 1 to grow Adaptive workflows have upside of ~10k USD/course “ Conventional Delivery SBRT Delivery The 2026 cuts brought the pain, and Elekta’s adaptive solutions
Slide 57: U.S. is driving a turnaround of the Linac business
United States Recap from last update | U.S. is driving a turnaround of the Linac business from our Adaptive leadership U.S. sales as share of Elekta Group sales, last 5 years Three commercial priorities for U.S., next 3 years BSEK 14.5 16.9 18.1 18.0 16.7 U.S. Commercializing our CT- and MR- Linacs
Slide 58: Evo and Unity Pro linacs are leading the Adaptive charge
United States Commercialization of CT- and MR-linacs Our Evo and Unity Pro linacs are leading the Adaptive charge What the U.S. customers want: • 15 min patient table times (CT-Linac) Elekta | Evo (+ Iris) • Autonomous and efficient SBRT delivery • Flexibility in workflow to adapt What the U.S. cust
Slide 59: Strong Evo commercialization momentum
United States Commercialization of CT- and MR-linacs Strong Evo commercialization momentum since market access Evo commercialization Retention of linac installed base $ ➢ Large wave of replacements & strong upgrading capability >30% Solutions order growth in the U.S. in FY25/26 Double-digit Evo unit
Slide 60: Service business to grow from increased volumes and attach rate
United States Growing our Service business Service business to grow from increased volumes & attach rate Share or service and software sales, % +4 p.p. • Profitable Service contracts to existing and new install base sales • Double-digit % price increases on Service contracts in last year 56% 60% • S
Slide 61: Strong penetration uptake for treatment planning software
United States Continue driving TPS penetration Strong penetration uptake for Elekta’s treatment planning software Product performance Commercial effects in U.S. ~50% 1.8 min YoY uptake in U.S. on Attaching profitable SW Treatment Planning to the installed base GPU-accelerated planning 30 min Sets up
Slide 62: U.S. sales target CAGR FY25/26 – FY28/29
United States Sales target CAGR FY25/26 – FY28/29 U.S. FY25/26 Mid-term targets • Sales growth in fixed Mid to High-single digit -6% currency CAGR FY25/26 – FY28/29 62
Slide 63: Focus is on three key markets
Markets Focus is on three key markets United Europe China States Arnaud Delhaye Ardie Ermers Anming Gong Head of Region Head of Region Head of Region Europe Americas China 63
Slide 64: China is recovering while competition intensifies
China China is recovering, fueled by unmet demand and expanding access, while competition intensifies despite our #1 position Total RT market 2025 by geography 1 ~18k 7.1BUSD • Market recovery with 270+ linacs expected for Europe ~25% 25–30% FY26/27 • Unmet demand remains significant (~3k installed
Slide 65: China market by player; local vendors gaining momentum
China China is recovering, fueled by unmet demand and expanding access, while competition intensifies despite our #1 position Total RT market 2025 by geography and China market by player 1 ~18k 7.1BUSD 100% Europe ~25% 25–30% ~40% Elekta • Local vendors are United States ~25% gaining momentum 30–35%
Slide 66: China remains a key market; defend and strengthen leading position
China China remains a key market for Elekta, where we will defend and strengthen our leading position China sales as share of Elekta Group sales, last 5 years Three commercial priorities for China, next 3 years BSEK Elekta ex. China China 14.5 16.9 18.1 18.0 16.7 Accelerate localization of R&D and m
Slide 67: Priorities to defend and strengthen position in China
China To defend and strengthen our market position in China, we will focus on a set of priorities Localized R&D Lifecycle value and through Strengthen innovation partnerships across the manufacturing partnerships ecosystem to reinforce market Accelerate localization of position and unlock lifecycle
Slide 68: China sales target CAGR FY25/26 – FY28/29
China Sales target CAGR FY25/26 – FY28/29 China FY25/26 Mid-term targets • Sales growth in fixed Mid-single digit -6% currency CAGR FY25/26 – FY28/29 68
Slide 69: Agenda
Agenda Speaker Time 1 Welcome & Introduction Peter Nyquist, Head of Investor Relations 5 min 2 Strategy & Targets Jakob Just-Bomholt, President & CEO 20 min Christopher Busch 3 Linac & Software Products Chief Product and Technology Officer 25 min Break 15 min Arnaud Delhaye, Head of Region Europe 4
Slide 70: Focus is on three financial topics
Financials Focus is on three financial topics Quality of Financial Capital earnings targets allocation 70
Slide 71: Focus is on three financial topics
Financials Focus is on three financial topics Quality of Financial Capital earnings targets allocation 71
Slide 72: Elekta is taking actions to improve quality of earnings
Financials Quality of earnings Elekta is taking actions to improve quality of earnings Operational improvements Increase transparency • Improved order book quality – predictable sales • Establish financial targets to support equity story • Relevant balance sheet – write-off and impairment • Cash flo
Slide 73: Improved backlog quality supports predictable growth
Financials Quality of earnings Improved backlog quality supports predictable growth Total order backlog FY25/26, BSEK Order backlog review 34 BSEK • Firmer interpretation of the order intake criteria 2.1x • Book to bill ratio to become stronger indicator of future growth FY 25/26 sales • Book to bil
Slide 74: Balance sheet aligned with strategy, improving quality of earnings
Financials Quality of earnings Balance sheet aligned with strategy, improving quality of earnings Rationale Items affecting comparability Q4 24/25 and Q4 25/26 • Better aligned balance sheet with current business • 1,823 MSEK – impairment of capitalized R&D projects assumptions o Follows implementat
Slide 75: Gross R&D expected to stabilize around 10% of sales
Financials Quality of earnings Gross R&D is expected to stabilize around 10% of sales with accelerated innovation velocity Development of R&D expenditures 1 Balancing capitalization with amortization 12.2% 12.2% 11.6% 10.0% 10% 10% 10% • Gross R&D at 10% of sales • After FY26/27 assuming capitalizat
Slide 76: Increased accountability with new decentralized operating model
Financials Quality of earnings Increased accountability and speed with Elekta’s new decentralized operating model 2025 operating model 2026 operating model Group Group Commercial • Regions fully responsible for P&L and balance sheet Region Region Region Region Region Products Products • Transparency
Slide 77: New operating model has resulted in OPEX savings ahead of guidance
Financials Quality of earnings Elekta’s new operating model has resulted in OPEX savings significantly ahead of Q2 guidance Adjusted OPEX development1, MSEK Comments 1,144 • Achieved net run rate saving of more than 500 1,029 MSEK of which 70% in OPEX 958 • New operating model brings transparency an
Slide 78: Focus is on three financial topics
Financials Focus is on three financial topics Quality of Financial Capital earnings targets allocation 78
Slide 79: Outlook for FY26/27
Financials Financial targets Outlook for FY26/27 FY25/26 FY26/27 Key drivers Sales growth in Sales 1% 2 – 4% fixed currency • Growth driven by all regions and services Adjusted EBIT 12.3% 12.5 – 13.5% margin1 EBIT margin • Improved pricing • Evo commercialization • Implementation of new operating mo
Slide 80: Mid-term financial targets FY28/29
Financials Financial targets Mid-term financial targets FY28/29 FY25/26 Mid-term targets Sales growth in fixed currency Mid-single digit 1% CAGR FY25/26 – FY28/29 Adjusted EBIT margin1 12.3% 14 – 16% FY28/29 (Assumes capitalization & amortization - Adjusted EBITC margin2 11.2% broadly in line) Free
Slide 81: Mid-term sales growth targets for key markets
Financials Financial targets Mid-term sales growth targets for key markets Mid-term targets Mid-single digit Europe CAGR FY25/26 – FY28/29 Sales growth Mid to High-single digit U.S. in fixed currency CAGR FY25/26 – FY28/29 Mid-single digit China CAGR FY25/26 – FY28/29 81
Slide 82: Adjusted EBIT margin target of 14-16%
Financials Financial targets Adjusted EBIT margin target of 14 – 16% Adjusted EBIT margin development 1, % Illustrative Key drivers of EBIT margin improvement 14-16% Gross Margin – return to pre-pandemic levels • Pricing and product cost reengineering (Must-Win Battle 4) to offset inflationary impac
Slide 83: Gross margin will improve gradually towards pre-pandemic levels
Financials Financial targets Gross margin will improve gradually towards pre-pandemic levels Adjusted Gross margin development 1, % Illustrative Key drivers of Gross margin improvement Towards Productivity measures offset cost inflation pre-pandemic • Continued margin leverage from the new operating
Slide 84: Approximately 10% of sales in free cash flow by FY28/29
Financials Financial targets By full year 2028/2029 Elekta is expected to generate approximately 10% of sales in free cash flow before dividend FY 28/29 % of sales Comment EBIT 14 to 16% Depreciation and Amortization 7 to 9% Add-back of depreciation and amortization Net working capital -1 to -2% Bui
Slide 85: Focus is on three financial topics
Financials Focus is on three financial topics Quality of Financial Capital earnings targets allocation 85
Slide 86: Capital allocation strategy to support profitability and growth
Financials Capital allocation Capital allocation strategy to support future profitability and growth ~10% free cash flow in FY28/29 allows approximately 2 BSEK available for growth or distribution to shareholders Strong cash flow and Balance sheet strength Shareholder distribution Innovation driven
Slide 87: Creating long-term shareholder value
Financials Capital allocation Creating long-term shareholder value Dividend is the primary In addition, capital can be alternative for distributing returned to shareholders Shareholder distribution capital to Elekta's through share buybacks in line shareholders at a minimum with the AGM mandate or o
Slide 88: Summary
Financials Summary Improve earnings quality by strengthening linkage between EBIT, balance sheet and cash flow Deliver on 14 – 16% EBIT target through adaptive commercialization, service growth and recurring software sales Solid cash flow allows investments in growth and increased shareholder distri
Slide 89: Agenda
Agenda Speaker Time 1 Welcome & Introduction Peter Nyquist, Head of Investor Relations 5 min 2 Strategy & Targets Jakob Just-Bomholt, President & CEO 20 min Christopher Busch 3 Linac & Software Products Chief Product and Technology Officer 25 min Break 15 min Arnaud Delhaye, Head of Region Europe 4
Slide 90: Concluding remarks: execute with speed to realize full potential
Concluding remarks Elekta will continue to take decisive action and execute with speed to realize our full potential over the next 3 years Elekta is not yet performing at our full potential; we have a plan in place to address this New operating model is in place to increase velocity of innovation an
Slide 91: Agenda
Agenda Speaker Time 1 Welcome & Introduction Peter Nyquist, Head of Investor Relations 5 min 2 Strategy & Targets Jakob Just-Bomholt, President & CEO 20 min Christopher Busch 3 Linac & Software Products Chief Product and Technology Officer 25 min Break 15 min Arnaud Delhaye, Head of Region Europe 4
Slide 92: Q&A
Q&A @Elekta
Slide 93: Nobody does adaptive like Elekta
Nobody does adaptive like Elekta
Slide 94: Elekta Capital Markets Day Presenters
Elekta Capital Markets Day Presenters Jakob Just-Bomholt Christopher Busch President & CEO Chief Product & Technology Officer Previously Head of Research & Engineering Previously CEO of 3Shape, Falck at Elekta, with earlier innovation and R&D Emergency Services and Seago Line, leadership roles at Ph
Slide 95: Elekta Capital Markets Day Presenters
Elekta Capital Markets Day Presenters Arnaud Delhaye Peter Nyquist Head of Region Europe Head of Investor Relations Previously Vice President of Global Sales Previously Head of Investor Relations at at Elekta, Surgical Robotics at Medtronic, Ericsson and Electrolux Group, and Head of Vice President
Slide 96: Glossary
Glossary Adaptive Radiotherapy (ART): A radiotherapy approach that adjusts the treatment plan during therapy to reflect patient and tumor changes. Adjusted EBIT margin: Earnings before interest and taxes, excluding items affecting comparability, as % of net sales. Adjusted EBITC margin: Earnings bef
Slide 97: Nobody does adaptive like Elekta
Nobody does adaptive like Elekta